AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Inositol-trisphosphate 3-kinase C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96DU7

UPID:

IP3KC_HUMAN

Alternative names:

Inositol 1,4,5-trisphosphate 3-kinase C

Alternative UPACC:

Q96DU7; Q9UE25; Q9Y475

Background:

Inositol-trisphosphate 3-kinase C plays a pivotal role in cellular processes by catalyzing the phosphorylation of 1D-myo-inositol 1,4,5-trisphosphate into 1D-myo-inositol 1,3,4,5-tetrakisphosphate, crucial for calcium homeostasis regulation. Its ability to also phosphorylate inositol 2,4,5-triphosphate highlights its versatility in cellular signaling pathways.

Therapeutic significance:

Understanding the role of Inositol-trisphosphate 3-kinase C could open doors to potential therapeutic strategies, especially in disorders related to calcium homeostasis and signaling pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.